JP2010516751A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516751A5
JP2010516751A5 JP2009546837A JP2009546837A JP2010516751A5 JP 2010516751 A5 JP2010516751 A5 JP 2010516751A5 JP 2009546837 A JP2009546837 A JP 2009546837A JP 2009546837 A JP2009546837 A JP 2009546837A JP 2010516751 A5 JP2010516751 A5 JP 2010516751A5
Authority
JP
Japan
Prior art keywords
subtype
nachr
antagonist
treating
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009546837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516751A (ja
Filing date
Publication date
Priority claimed from US11/698,131 external-priority patent/US20070224284A1/en
Application filed filed Critical
Publication of JP2010516751A publication Critical patent/JP2010516751A/ja
Publication of JP2010516751A5 publication Critical patent/JP2010516751A5/ja
Withdrawn legal-status Critical Current

Links

JP2009546837A 2007-01-26 2008-01-11 少なくとも１種類のα３β４ｎＡＣｈＲ拮抗薬又はその製薬的に受容される塩を含む方法及び組成物 Withdrawn JP2010516751A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/698,131 US20070224284A1 (en) 2004-03-12 2007-01-26 Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
PCT/IB2008/000905 WO2008090471A2 (en) 2007-01-26 2008-01-11 Use of compositions comprising at least one alfa3 beta4 nachr antagonist such as mecamylamine in the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
JP2010516751A JP2010516751A (ja) 2010-05-20
JP2010516751A5 true JP2010516751A5 (enExample) 2011-03-03

Family

ID=38533754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546837A Withdrawn JP2010516751A (ja) 2007-01-26 2008-01-11 少なくとも１種類のα３β４ｎＡＣｈＲ拮抗薬又はその製薬的に受容される塩を含む方法及び組成物

Country Status (4)

Country Link
US (3) US20070224284A1 (enExample)
EP (1) EP2106259A2 (enExample)
JP (1) JP2010516751A (enExample)
WO (1) WO2008090471A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
KR102354954B1 (ko) 2016-04-04 2022-01-24 오메자 엘엘씨 어유 국소 조성물
CN107095935A (zh) * 2017-03-29 2017-08-29 黄河科技学院 一种中药组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916903A (en) * 1997-02-28 1999-06-29 Synapse Pahrmaceuticals International, Inc. Method for reducing the effects of antineoplastic disease treatment
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
WO2000033812A2 (en) 1998-12-07 2000-06-15 Elan Corporation, Plc Transdermal patch for delivering volatile liquid drugs
AU2368200A (en) 1998-12-16 2000-07-03 University Of South Florida Exo-r-mecamylamine formulation and use in treatment
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
EP1603544B1 (en) * 2003-03-14 2007-10-10 AGI Therapeutics Research Limited Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine

Similar Documents

Publication Publication Date Title
NO2020027I1 (no) glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2019042I1 (no) Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
JP2012144574A5 (enExample)
JP2015504870A5 (enExample)
JP2009039101A5 (enExample)
NO2018028I1 (no) Alogliptin i kombinasjon med plaglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
JP2014507446A5 (enExample)
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
JP2012107057A5 (enExample)
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
HRP20171197T1 (hr) Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze
JP2009535462A5 (enExample)
WO2007149797A3 (en) Use of organic compounds
JP2009545527A5 (enExample)
JP2011006431A5 (enExample)
JP2012072162A5 (enExample)
JP2010059183A5 (enExample)
JP2009536652A5 (enExample)
IL219610A (en) Preparations containing a history of 3-hydroxy-2-oxo-1,2-dihydropyridine for use in the treatment or preparation of a drug for the treatment of epithelial tissue inflammation
JP2011518833A5 (enExample)
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
JP2009506080A5 (enExample)
JP2016512817A5 (enExample)
JP2015522522A5 (enExample)